Emisphere Appoints Two New Board Members

Dec 11, 2003, 00:00 ET from Emisphere Technologies, Inc.

    TARRYTOWN, N.Y., Dec. 11 /PRNewswire-FirstCall/ -- Emisphere Technologies,
 Inc. (Nasdaq:   EMIS) today announced that two new independent members, Stephen
 K. Carter, M.D., and Michael E. Black, have been appointed to its Board of
 Directors, and that Joseph R. Robinson, Ph.D., and Jere E. Goyan, Ph.D., have
 resigned their board positions and have become consultants to Emisphere.
     Michael M. Goldberg, M.D., Chairman and Chief Executive Officer of
 Emisphere, stated, "We are very pleased to appoint two new independent members
 to the Board, each of whom brings skills and experience that will be of great
 value to our company.  Dr. Stephen Carter's breadth of experience in
 pharmaceutical research and development and pharmaceutical product licensing,
 position him to provide important contributions relative to our business
 strategy of maximizing the value of our current and future product candidates
 for potential partnering.  Michael Black, with over 30 years of expertise in
 strategic planning and organizational and leadership development, and over 15
 years of administrative experience in academic medicine, will bring an
 important perspective on, among other matters, Company organization, processes
 and practices."
     Dr. Stephen Carter is the former Senior Vice President, Clinical and
 Regulatory Affairs, of Sugen, Inc. (ownership of Sugen has since passed to
 Pfizer, Inc. as part of its acquisition of Pharmacia in April 2003). Dr.
 Carter previously was the Senior Vice President, Research and Development of
 Boehringer Ingelheim Pharmaceuticals, Inc., now independently owned.
 Previously, he served 13 years at Bristol-Myers Squibb Co., including, as its
 Senior Vice President, Worldwide Clinical Research and Development.  Prior to
 Bristol-Myers' acquisition of Squibb, he served as President and Senior Vice
 President of the Pharmaceutical Research and Development division.
     Dr. Carter is a former Deputy Director at the National Cancer Institute
 (NCI)'s Division of Cancer Treatment.  He received his Medical Doctorate from
 New York Medical College and served his residency at Lenox Hill Hospital in
 New York, New York, where he became Chief Medical Resident.  He is a member of
 the American Society of Clinical Oncology and other prominent cancer
 organizations and has been affiliated for over 30 years with academic
 journals, as a co-editor or seated on their editorial review boards.  He is
 currently a member of the boards of directors of Alfacell Corporation,
 Achillion Pharmaceuticals, Inc., Cytogen Corporation, Sopherion Therapeutics,
 Inc., and Vion Pharmaceuticals, Inc.
     Mr. Michael Black is the Vice Dean for Administration and Finance at the
 University of Pennsylvania School of Medicine. Prior to assuming this
 position, Mr. Black was Vice Dean at Creighton University, where he also
 served in other executive roles.  Mr. Black was also, in succession, the Chief
 Financial, Operating and Executive Officer for the United States Air Force
 Health Care Administration Division.  Mr. Black received his M.B.A. from
 Golden Gate University in San Francisco.  He is also a member of the Medical
 Group Management Association, and a member of the Association of American
 Medical Colleges.
     Dr. Goldberg stated, "We look forward to benefiting from the combined
 wealth of experience that Dr. Carter and Mr. Black will bring to our Board.
 We also gratefully acknowledge the contributions provided by Drs. Robinson and
 Goyan in their respective five and 11 years of service on our Board of
 Directors.  We are pleased that both have agreed to remain involved with
 Emisphere in consulting roles, so that we can continue to benefit from their
 knowledge and experience."
     Emisphere's Board will now consist of seven members, of whom six are
 independent.  To view a current list of Emisphere's Board of Directors, please
 visit the overview portion of the Emisphere website:  www.emisphere.com .
     About Emisphere Technologies, Inc.
     Emisphere Technologies, Inc. (Nasdaq:   EMIS) is a biopharmaceutical company
 pioneering the oral delivery of otherwise injectable or inhaled drugs.  It is
 in the business of licensing its proprietary eligen(TM) oral drug delivery
 technology to partners who apply it directly to their marketed drugs.
 Emisphere conducts proof-of-concept clinical trials and other early-stage
 trials to advance the technology and increase value for potential partnering
 opportunities. Emisphere's eligen(TM) technology has facilitated the oral
 delivery of proteins, peptides, macromolecules and charged organics.
 Emisphere and its partners have advanced oral formulations of salmon
 calcitonin, heparin, insulin, parathyroid hormone, human growth hormone and
 cromolyn sodium   into clinical trials.  Four oral drug formulations
 containing EMISPHERE(R) delivery agents have been accepted for clinical
 testing in the U.S.  Emisphere develops pharmaceutical products for its own
 portfolio and has strategic alliances with some of the world's leading
 pharmaceutical and biotechnology companies. For further information, please
 visit www.emisphere.com .
     Safe Harbor Statement Regarding Forward-looking Statements
     The statements in this release and oral statements made by representatives
 of Emisphere relating to matters that are not historical facts (including
 without limitation those regarding the timing or potential outcomes of
 research collaborations or clinical trials, any market that might develop for
 any of Emisphere's product candidates and the sufficiency of Emisphere's cash
 and other capital resources) are forward-looking statements that involve risks
 and uncertainties, including, but not limited to, the likelihood that future
 research will prove successful, the likelihood that any product in the
 research pipeline will receive regulatory approval in the United States or
 abroad, the ability of Emisphere and/or its partners to develop, manufacture
 and commercialize products using Emisphere's drug delivery technology,
 Emisphere's ability to fund such efforts with or without partners, and other
 risks and uncertainties detailed in Emisphere's filings with the Securities
 and Exchange Commission, including those factors discussed under the caption
 "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
 filed on March 31, 2003. Emisphere disclaims any responsibility to update any
 of such forward-looking statements.

SOURCE Emisphere Technologies, Inc.